Who Paid My Doc
Steven Herbst
Foot and Ankle Surgery Muncie, IN Medical Doctor
NPI 1588671788 CMS profile 71303
3600 W Bethel Ave, Muncie, IN 47304
General payments
$1,550,380
Research payments
$0
Ownership & investment interest
$214,860
Through program year 2025, Steven Herbst of Muncie, IN is reported in the CMS Open Payments database as having received $1,550,380 across 291 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $214,860 across 2 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $70,236 | 23 | |
| 2024 | General | $88,914 | 33 | |
| 2023 | General | $69,924 | 50 | |
| 2022 | General | $903,609 | 31 | |
| 2021 | General | $232,678 | 64 | |
| 2020 | General | $64,123 | 20 | |
| 2019 | General | $120,894 | 70 | |
| 2022 | Ownership | $114,860 | 1 | |
| 2021 | Ownership | $100,000 | 1 |
Beside peers
- Steven Herbst
- Foot and Ankle Surgery median
- Middle half of Foot and Ankle Surgery
- National median
In program year 2025, general payments to Steven Herbst were reported at $70,236. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.
Show as a table
| Year | Steven Herbst | Foot and Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $120,894 | $1,327 | $279–$5,421 | $163 |
| 2020 | $64,123 | $795 | $121–$3,473 | $114 |
| 2021 | $232,678 | $1,289 | $201–$4,963 | $132 |
| 2022 | $903,609 | $1,539 | $270–$6,067 | $149 |
| 2023 | $69,924 | $1,117 | $257–$5,264 | $160 |
| 2024 | $88,914 | $1,064 | $235–$4,944 | $164 |
| 2025 | $70,236 | $1,183 | $267–$6,309 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
337
Drug cost
$3,282
Branded share of claims
62.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 123 | $1,505 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 68 | $826 | |
| Gabapentin | Generic | 47 | $444 | |
| Cephalexin | Generic | 42 | $243 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 20 | $108 | |
| Methylprednisolone | Generic | 13 | $94 | |
| Tramadol Hcl | Generic | 24 | $62 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 87 billing codesPaid by Medicare
$126,249
Medicare patients
365
Services billed
18,478
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 70% | |
| Depression | 28% | |
| Chronic kidney disease | 24% | |
| Diabetes | 23% | |
| Ischemic heart disease | 21% | |
| Cancer | 15% | |
| Atrial fibrillation | 14% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 133 | 16,688 | $1,687 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 80 | 126 | $377 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
291 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Foot and Ankle Surgery in Indiana
Kevin Anderson
Foot and Ankle Surgery · South Bend, IN
Andrew Wohler
Foot and Ankle Surgery · Carmel, IN
Stephen Greenfield
Foot and Ankle Surgery · Indianapolis, IN
Mihir Patel
Foot and Ankle Surgery · Indianapolis, IN
James Flynn
Foot and Ankle Surgery · South Bend, IN
Erica Fisk
Foot and Ankle Surgery · Fishers, IN
Related records
Foot and Ankle Surgery in Indiana
Practitioners in the same specialty and state, ranked by reported value.
All Foot and Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Indiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.